Dulaglutide Research Dosage: Published Protocol Reference
Dulaglutide dosage references vary by route and study context. The database lists Subcutaneous injection: 0.75 mg, Once weekly and Subcutaneous injection: 1.5 mg or 3.0 mg or 4.5 mg, Once weekly. These are research-context references, not a universal protocol.
Direct Answer
Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes and cardiovascular risk reduction, with the REWIND trial demonstrating significant CV event reduction in a broad diabetic population. As a once-weekly GLP-1 agonist, it offers meaningful convenience. Its weight-loss efficacy is modest compared to semaglutide, but its CV outcome data is robust. A well-validated option for GLP-1 pathway research with strong regulatory backing.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Best for
- Type 2 diabetes management, cardiovascular risk reduction, once-weekly GLP-1 agonism
Research Dosage References
- <strong>Subcutaneous injection</strong> - 0.75 mg - Once weekly - Starting dose. Can be administered at any time of day with or without meals. Available as a pre-filled, single-dose pen.
- <strong>Subcutaneous injection</strong> - 1.5 mg or 3.0 mg or 4.5 mg - Once weekly - Dose may be increased for additional glycemic control. The 3.0 mg and 4.5 mg doses were approved in 2020 for enhanced efficacy.
Half-Life
~5 days.
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Dulaglutide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Boxed warning: Thyroid C-cell tumor risk in rodents
- Contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2
- Risk of pancreatitis - discontinue if suspected
- Caution in patients with renal impairment
- Not for use in type 1 diabetes or diabetic ketoacidosis
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Glycemic Control (Level A), Cardiovascular Risk Reduction (Level A), and Body Weight Reduction (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Dulaglutide Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/dulaglutide-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.